StreetInsider.com News Articles

Form 144 Cogent Biosciences, Inc. Filed by: Morris Arlene

Thu, 27 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260827/26990156.html

Form 144 Cogent Biosciences, Inc. Filed by: Morris Arlene

Thu, 27 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260827/26990156.html

H.C. Wainwright Reiterates Buy Rating on Cogent (COGT)

Thu, 20 Aug 2026 06:53:37 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $55.00 price target on Cogent (NASDAQ: COGT).

The analyst commented: "Financial results reported—raising price target. For 2Q26, Cogent recorded a net loss of $0.56 vs. our previously forecasted net loss of $0.55 per share. R&D and SG&A expenses were $70.8M and $31.8M, respectively, vs. our estimates of $72.5M and $28.4M. We now project a full-year 2026 net loss of $2.37 per share compared to our prior estimate of $2.21 per share. Cogent ended 2Q26 with $865.9M in cash and equivalents, which should provide an operational runway into late 2028. We note,

Cogent (COGT) PT Raised to $55 at Piper Sandler

Mon, 17 Aug 2026 07:43:38 -0400

Piper Sandler analyst Allison M. Bratzel raised the price target on Cogent (NASDAQ: COGT) to $55.00 (from $52.00) while maintaining a Overweight rating.

Form SCHEDULE 13G/A Cogent Biosciences, Inc. Filed by: Flynn James E

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921099.html

Form SCHEDULE 13G/A Cogent Biosciences, Inc. Filed by: Flynn James E

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921099.html

Cogent (COGT) PT Raised to $52 at Guggenheim

Wed, 12 Aug 2026 06:56:15 -0400

(Updated - August 12, 2026 6:56 AM EDT)

Guggenheim analyst Charles Zhu raised the price target on Cogent (NASDAQ: COGT) to $52.00 (from $45.00) while maintaining a Buy rating.

The analyst commented: "COGT reported 2Q26 earnings and remains on track for two near term FDA decisions on bezuclastinib (KIT inhibitor): 2L GIST (in combination with sunitinib) with a PDUFA date of November 30, 2026, and NonAdvSM with a PDUFA date of December 30, 2026. The AdvSM NDA was submitted on June 30 following positive full APEX data at EHA (here), which showed a competitive efficacy profile vs. Ayvakit alongside a differentiated safety

Cogent (COGT) PT Raised to $52 at Guggenheim

Wed, 12 Aug 2026 06:56:15 -0400

(Updated - August 12, 2026 6:56 AM EDT)

Guggenheim analyst Charles Zhu raised the price target on Cogent (NASDAQ: COGT) to $52.00 (from $45.00) while maintaining a Buy rating.

Form 8-K Cogent Biosciences, Inc. For: Aug 10

Mon, 10 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260810/26899200.html

Form 8-K Cogent Biosciences, Inc. For: Aug 10

Mon, 10 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260810/26899200.html

Form 424B5 Cogent Biosciences, Inc.

Mon, 10 Aug 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260810/26899181.html

Form 424B5 Cogent Biosciences, Inc.

Mon, 10 Aug 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260810/26899181.html

Form 10-Q Cogent Biosciences, Inc. For: Jun 30

Mon, 10 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260810/26898005.html

Form 10-Q Cogent Biosciences, Inc. For: Jun 30

Mon, 10 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260810/26898005.html

Form 8-K Cogent Biosciences, Inc. For: Aug 10

Mon, 10 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260810/26894813.html

Form 8-K Cogent Biosciences, Inc. For: Aug 10

Mon, 10 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260810/26894813.html

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Mon, 10 Aug 2026 08:00:00 -0400

On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June 30